seekingalpha.com · 16 jun

Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopathy and upcoming pivotal data for Zenkuda, KSI-501, and KSI-101 underpin a bullish outlook. KOD's current $169.5M cash position supports near-term catalysts, but additional capital will be needed for commercialization and late-stage development.

fool.com · 9 jun

Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know

This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.

zacks.com · 4 jun

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.

prnewswire.com · 28 may

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.

fool.com · 17 may

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

zacks.com · 8 may

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.

prnewswire.com · 7 may

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.

prnewswire.com · 1 may

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.